RAPT Narrows Losses, Secures $234M Funding for Clinical Trials

TL;DR

RAPT's massive capital raise and reduced burn rate make it a speculative buy as clinical trials for ozureprubart and tivumecirnon advance.

AI Summary

RAPT Therapeutics, Inc. reported a net loss of $17.58 million for the three months ended September 30, 2025, an improvement from a net loss of $18.43 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $52.388 million, significantly lower than the $76.616 million loss in the prior year. Research and development expenses decreased to $36.416 million for the nine months ended September 30, 2025, from $60.761 million in 2024, reflecting a strategic shift including the cessation of zelnecirnon development in November 2024. The company's cash and cash equivalents decreased from $169.735 million at December 31, 2024, to $37.930 million at September 30, 2025, with $76.143 million used in operating activities during the nine-month period. However, a significant capital infusion occurred in October 2025, with an underwritten public offering generating approximately $234.4 million in net proceeds from 8,333,334 shares at $30.00 per share. This financing is expected to provide sufficient funds for at least 12 months, supporting the Phase 2b clinical trial of ozureprubart in food allergy, initiated in October 2025, and continued development of tivumecirnon.

Why It Matters

This filing is crucial for investors as RAPT Therapeutics, a clinical-stage biopharmaceutical company, has significantly reduced its net loss and secured substantial financing. The $234.4 million raised in October 2025 provides a critical cash runway for at least 12 months, enabling continued development of key drug candidates like ozureprubart for food allergy and tivumecirnon for oncology. This capital injection mitigates immediate liquidity concerns and allows RAPT to advance its pipeline, potentially increasing its competitive standing against larger pharmaceutical companies in the immunology and oncology spaces. Employees and customers benefit from the increased stability and continued pursuit of novel therapies, while the broader market watches for progress in these high-demand therapeutic areas.

Risk Assessment

Risk Level: medium — The company incurred a net loss of $52.388 million and used $76.143 million in operating activities for the nine months ended September 30, 2025, indicating continued cash burn. While the October 2025 public offering of $234.4 million significantly improved liquidity, the company still relies on future financing or strategic alliances, and its drug candidates, ozureprubart and tivumecirnon, are in clinical stages, carrying inherent development and regulatory risks.

Analyst Insight

Investors should monitor the progress of RAPT's clinical trials for ozureprubart and tivumecirnon closely, as successful advancement could significantly impact valuation. The recent $234.4 million capital raise provides a buffer, but future financing needs and the inherent risks of drug development mean this remains a high-growth, high-risk investment.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$52.388M

eps

N/A

gross Margin

N/A

cash Position

$37.930M

revenue Growth

N/A

Key Numbers

• $52.388M — Net Loss (For the nine months ended September 30, 2025, a decrease from $76.616M in 2024.)
• $234.4M — Net Proceeds from Public Offering (Raised in October 2025, significantly boosting liquidity.)
• $76.143M — Net Cash Used in Operating Activities (For the nine months ended September 30, 2025.)
• $37.930M — Cash and Cash Equivalents (As of September 30, 2025, before the October 2025 offering.)
• 8,333,334 — Shares Issued (In the October 2025 public offering.)
• 1-for-8 — Reverse Stock Split (Effected on June 16, 2025.)
• $36.416M — Research and Development Expenses (For the nine months ended September 30, 2025, down from $60.761M in 2024.)
• 12 months — Cash Runway (Expected duration of funds after October 2025 offering.)
• $157.3M — Cash and Marketable Securities (As of September 30, 2025, prior to the October 2025 offering.)
• $14.214M — Stock-based Compensation Expense (For the nine months ended September 30, 2025.)

Key Players & Entities

• RAPT Therapeutics, Inc. (company) — registrant
• ozureprubart (drug) — lead drug candidate for food allergy
• tivumecirnon (drug) — oncology drug candidate
• Brian Wong, M.D., Ph.D. (person) — Chief Executive Officer and CODM
• Nasdaq Global Market (regulator) — exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• $234.4 million (dollar_amount) — net proceeds from October 2025 public offering
• $30.00 (dollar_amount) — price per share in October 2025 public offering
• $52.388 million (dollar_amount) — net loss for the nine months ended September 30, 2025
• $76.143 million (dollar_amount) — net cash used in operating activities for the nine months ended September 30, 2025

FAQ

Risk Factors

• Substantial doubt about liquidity [high — financial]: The company has incurred significant losses and negative cash flows from operations, with $76.143 million used in operating activities for the nine months ended September 30, 2025. While a $234.4 million capital infusion occurred in October 2025, the company's ability to continue as a going concern is dependent on future financing and successful development and commercialization of its product candidates.
• Clinical trial and drug development risks [high — operational]: RAPT Therapeutics is heavily reliant on the success of its clinical trials, particularly the Phase 2b trial of ozureprubart and the continued development of tivumecirnon. Delays, adverse results, or failure to obtain regulatory approval for these candidates could materially impact the company's future prospects.
• Regulatory approval uncertainty [high — regulatory]: The development and commercialization of pharmaceutical products are subject to stringent regulatory review by agencies like the FDA. Obtaining approval for ozureprubart and tivumecirnon involves significant time, expense, and uncertainty, with no guarantee of success.
• Dependence on future financing [medium — financial]: The company has historically relied on equity financings to fund its operations. The October 2025 offering provided substantial proceeds, but continued development and potential commercialization will likely require additional capital, the availability of which is not assured.
• Cessation of zelnecirnon development [medium — operational]: The decision to cease development of zelnecirnon in November 2024, while reducing R&D expenses, indicates the inherent risks and potential setbacks in drug development and may impact the company's pipeline diversification.
• Competition in target markets [medium — market]: The company operates in competitive therapeutic areas, including food allergy and oncology. The success of its product candidates will depend on their ability to demonstrate superior efficacy and safety compared to existing or emerging treatments.

Industry Context

RAPT Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics for serious diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding to advance drug candidates through development and potential commercialization.

Regulatory Implications

The company's drug candidates are subject to rigorous review by regulatory bodies like the FDA. Any delays in clinical trials, adverse findings, or failure to meet stringent efficacy and safety standards could prevent market approval, significantly impacting the company's future. The cessation of zelnecirnon development also highlights the inherent regulatory risks in drug development.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for ozureprubart and tivumecirnon.
2. Assess the burn rate and cash runway post-October 2025 financing.
3. Evaluate competitive landscape and differentiation of RAPT's pipeline candidates.
4. Consider the impact of the reverse stock split on trading liquidity and investor perception.

Key Dates

• 2025-10-01: Initiation of Phase 2b clinical trial of ozureprubart — Marks a critical step in the development of a key pipeline asset, with potential to validate the drug's efficacy in a larger patient population.
• 2025-10-01: Underwritten public offering completed — Raised approximately $234.4 million in net proceeds, significantly strengthening the company's financial position and extending its cash runway.
• 2025-06-16: Reverse stock split effected — A 1-for-8 reverse stock split was implemented, likely to increase the per-share trading price and meet exchange listing requirements.
• 2024-11-01: Cessation of zelnecirnon development — Strategic decision to discontinue a drug candidate, impacting R&D expenses and pipeline focus.

Glossary

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (RAPT Therapeutics reported a net loss of $52.388 million for the nine months ended September 30, 2025, indicating ongoing investment in research and development without current revenue generation.)

Cash and Cash Equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments with original maturities of three months or less. (The company's cash position decreased to $37.930 million as of September 30, 2025, highlighting the need for the subsequent capital raise.)

Net Cash Used in Operating Activities

The net amount of cash spent or received from the normal day-to-day business operations of a company. (RAPT Therapeutics used $76.143 million in operating activities for the nine months ended September 30, 2025, reflecting significant R&D expenditures.)

Reverse Stock Split

A corporate action in which a company reduces the number of its outstanding shares by consolidating them. (RAPT Therapeutics effected a 1-for-8 reverse stock split on June 16, 2025, to increase its stock price.)

Stock-based Compensation Expense

The cost recognized for equity awards granted to employees and directors, such as stock options and restricted stock units. (This expense was $14.214 million for the nine months ended September 30, 2025, representing a significant non-cash operating expense.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company's substantial losses and cash burn raise questions about its ability to continue as a going concern, although the recent financing is expected to mitigate this for at least 12 months.)

Year-Over-Year Comparison

RAPT Therapeutics has significantly reduced its net loss for the nine months ended September 30, 2025, to $52.388 million from $76.616 million in the prior year, primarily due to a decrease in R&D expenses following the cessation of zelnecirnon development. However, cash reserves have dwindled to $37.930 million before a substantial capital raise in October 2025, which injected approximately $234.4 million. This financing is critical for sustaining operations and advancing key clinical programs, mitigating near-term liquidity concerns.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock $0.0001 par value per share RAPT Nasdaq Glo

Filing Documents

• rapt-20250930.htm (10-Q) — 2239KB
• rapt-ex31_1.htm (EX-31.1) — 18KB
• rapt-ex31_2.htm (EX-31.2) — 18KB
• rapt-ex32_1.htm (EX-32.1) — 20KB
• 0001193125-25-268141.txt ( ) — 7025KB
• rapt-20250930.xsd (EX-101.SCH) — 845KB
• rapt-20250930_htm.xml (XML) — 1094KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Statements of Operations and Comprehensive Loss for the Three- and Nine-Months Ended September 30, 2025 and 2024 6 Condensed Statements of Stockholders' Equity for the Nine-Months Ended September 30, 2025 and 2024 7 Condensed Statements of Cash Flows for the Nine-Months Ended September 30, 2025 and 2024 8 Notes to Condensed Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 70 Item 3. Defaults Upon Senior Securities 70 Item 4. Mine Safety Disclosures 70 Item 5. Other Information 71 Item 6. Exhibits 72

Signatures

Signatures This Quarterly Report on Form 10-Q (this "Quarterly Report") includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Quarterly Report are the property of their respective owners. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Quarterly Report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about: estimates of our total addressable markets, future revenue, expenses, capital requirements, cash runway and our needs for additional financing; the initiation, cost, timing, progress and results of research and development activities, preclinical studies and clinical trials with respect to ozureprubart (formerly RPT904), tivumecirnon and other potential future drug candidates; our ability to identify, develop and commercialize drug candidates; our

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements RAPT THERAPEUTICS, INC. CONDENSED B ALANCE SHEETS (In thousands) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 37,930 $ 169,735 Marketable securities 119,414 61,320 Prepaid expenses and other current assets 3,701 4,181 Total current assets 161,045 235,236 Property and equipment, net 765 1,367 Operating lease right-of-use assets 1,883 3,333 Other assets 2,046 389 Total assets $ 165,739 $ 240,325 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,102 $ 1,275 Accrued expenses 9,008 9,597 License fees payable — 35,000 Operating lease liabilities, current 2,209 2,422 Other current liabilities 56 57 Total current liabilities 13,375 48,351 Operating lease liabilities, non-current 387 2,070 Total liabilities 13,762 50,421 Commitments and contingencies Stockholders' equity: Preferred stock — — Common stock 2 13 Additional paid-in capital 818,810 804,388 Accumulated other comprehensive income 100 50 Accumulated deficit ( 666,935 ) ( 614,547 ) Total stockholders' equity 151,977 189,904 Total liabilities and stockholders' equity $ 165,739 $ 240,325 See accompanying notes to condensed financial statements. 5 RAPT THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPER ATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 12,034 $ 13,340 $ 36,416 $ 60,761 General and administrative 7,337 6,448 21,755 20,875 Total operating expenses 19,371 19,788 58,171 81,636 Loss from operations ( 19,371 ) ( 19,788 ) ( 58,171 ) ( 81,636 ) Other income, net 1

View Full Filing

View this 10-Q filing on SEC EDGAR